After the market closes, several major companies are poised to release their quarterly earnings reports. Among them, Intel (INTC) is anticipated to report zero change in earnings, according to market consensus. This stands out as investors await insights into how the tech giant is navigating current industry challenges.
Other significant companies scheduled to announce their performance include Alphabet (GOOG, GOOGL), with an earnings consensus of $2.01 per share, and T-Mobile (TMUS), which is expected to report earnings of $2.47 per share. Gilead Sciences (GILD, Financial) is also on the docket, with analysts predicting earnings of $1.77 per share.
These reports are crucial as they provide a snapshot of how these companies are performing amid prevailing economic conditions. Analysts and investors will be particularly interested in the guidance these firms might provide for the coming quarters, as it could influence market dynamics moving forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Gilead Sciences Inc (GILD, Financial) is $112.27 with a high estimate of $140.00 and a low estimate of $82.00. The average target implies an upside of 5.53% from the current price of $106.39. More detailed estimate data can be found on the Gilead Sciences Inc (GILD) Forecast page.
Based on the consensus recommendation from 30 brokerage firms, Gilead Sciences Inc's (GILD, Financial) average brokerage recommendation is currently 2.1, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Gilead Sciences Inc (GILD, Financial) in one year is $80.51, suggesting a downside of 24.33% from the current price of $106.39. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Gilead Sciences Inc (GILD) Summary page.
GILD Key Business Developments
Release Date: February 11, 2025
- Total Product Sales (Excluding Veklury): $26.8 billion for the full year 2024, up 8% year-over-year.
- Fourth Quarter Product Sales (Excluding Veklury): $7.2 billion, up 13% year-over-year.
- HIV Sales: $19.6 billion for the full year 2024, up 8% year-over-year.
- Biktarvy Sales Growth: 13% year-over-year.
- Livdelzi Sales: $30 million in the fourth quarter of 2024.
- Oncology Sales: $3.3 billion for the full year 2024, up 12% year-over-year.
- Trodelvy Sales: $1.3 billion for the full year 2024, up 24% year-over-year.
- Cell Therapy Sales: $2 billion for the full year 2024.
- Veklury Sales: $1.8 billion for the full year 2024, down 18% year-over-year.
- Operating Income: $8.5 billion for the full year 2024.
- Non-GAAP EPS: $4.62 for the full year 2024.
- SG&A Expenses: $5.9 billion for the full year 2024, down 3% year-over-year.
- R&D Expenses: $5.7 billion for the full year 2024, flat year-over-year.
- Dividend Increase: 2.6% increase to $0.79 per share for 2025.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Gilead Sciences Inc (GILD, Financial) reported strong revenue growth, with total product sales excluding Veklury increasing by 8% year-over-year to $26.8 billion.
- The HIV segment showed significant growth, with full-year sales increasing by 8% to $19.6 billion, driven by the success of Biktarvy, which grew 13%.
- The company is making progress in its oncology segment, with Trodelvy sales increasing by 24% year-over-year, highlighting its role in metastatic breast cancer treatment.
- Gilead Sciences Inc (GILD) is advancing its pipeline with promising developments in HIV prevention, including the potential launch of lenacapavir, which has received Breakthrough Therapy designation.
- The liver disease portfolio, including the launch of Livdelzi, contributed to a 9% increase in sales, reflecting strong demand and market acceptance.
Negative Points
- The anticipated impact of Medicare Part D reform is expected to affect 2025 revenue by approximately $1.1 billion, with $900 million impacting the HIV segment.
- Veklury sales declined by 53% year-over-year in the fourth quarter, reflecting lower COVID-19 hospitalizations and contributing to overall revenue headwinds.
- Competitive dynamics in the cell therapy market pose challenges, with new launches affecting sales growth in the US and Europe.
- The company faces potential litigation costs related to promotional speaker programs for HIV medicines, impacting SG&A expenses.
- Foreign exchange headwinds are expected to offset approximately 1% of expected growth in 2025, adding to the financial challenges.
